Thrombocytopenia · patients with active cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health related quality of life · patients with active cancer with venous thromboembolism
1 finding from 1 review
All‐cause mortality · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent venous thromboembolism · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
It is very uncertain whether probiotics changes any diarrhoea compared with other active treatment (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · participants with cancer treated with radiotherapy (with or without chemotherapy)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade ≥ 3 diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
Probiotics may leads to lower severity of diarrhoea: grade 3 or higher compared with other active treatment (low certainty).
1 finding from 1 review
Time to rescue medication ‐ not measured · participants with cancer treated with radiotherapy (with or without chemotherapy)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Requiring rescue medication for diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
It is very uncertain whether probiotics changes requiring rescue medication for diarrhoea compared with other active treatment (very low certainty).
1 finding from 1 review
Adverse events · participants with cancer treated with radiotherapy (with or without chemotherapy)
1 finding from 1 review
All‐cause mortality · participants with cancer treated with radiotherapy (with or without chemotherapy)
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in induction of clinical remission CDAI < 150 compared with placebo (low certainty).
1 finding from 1 review
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 70‐point clinical response CDAI compared with placebo (low certainty).
1 finding from 1 review
Induction of 5‐point endoscopic response CDEIS · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 5‐point endoscopic response CDEIS compared with placebo (low certainty).
1 finding from 1 review
Sleep disturbance (adverse event) · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in sleep disturbance (adverse event) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in withdrawals due to adverse outcomes compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality Up to 28 days following admission · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 28 days following admission compared with inactive Control (moderate certainty).
1 finding from 1 review
Arterial thrombotic events ‐ up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Prophylactic trials: intervention showed no clear difference in arterial thrombotic events Up to 30 days post‐operatively compared with inactive control (low certainty).
2 findings from 1 review
Venous thrombotic events Up to 4 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thromboembolic events at 1 to 2 years · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review